SPRUCE BIOSCIENCES, INC.SPRBEarnings & Financial Report
Spruce Biosciences, Inc. is a late-stage biopharmaceutical firm focused on developing targeted therapies for rare endocrine and metabolic disorders with high unmet medical need. Its core pipeline includes candidates for congenital adrenal hyperplasia and Cushing’s syndrome, serving patients across North America, Europe and other developed markets.
SPRB Q4 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-11.1M
Net Profit
$-14.6M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-32.43
SPRUCE BIOSCIENCES, INC. Q4 FY2025 Financial Summary
SPRUCE BIOSCIENCES, INC. reported revenue of $0 for Q4 FY2025, with a net profit of $-14.6M (up 37.8% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-14.6M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
SPRUCE BIOSCIENCES, INC. Annual Revenue by Year
SPRUCE BIOSCIENCES, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $0).
SPRUCE BIOSCIENCES, INC. Quarterly Revenue & Net Profit History
SPRUCE BIOSCIENCES, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $-14.6M | N/A |
| Q3 FY2025 | $0 | — | $-8.2M | N/A |
| Q2 FY2025 | $0 | — | $-2.1M | N/A |
| Q1 FY2025 | $0 | — | $-14.0M | N/A |
| Q4 FY2024 | $697.0K | -75.9% | $-23.6M | -3380.1% |
| Q3 FY2024 | $602.0K | -80.4% | $-8.7M | -1440.4% |
| Q2 FY2024 | $1.6M | -25.6% | $-9.2M | -570.2% |
| Q1 FY2024 | $2.0M | +1.9% | $-11.6M | -580.7% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $1.6M | $602000 | $697000 | $0 | $0 | $0 | $0 |
| YoY Growth | 1.9% | -25.6% | -80.4% | -75.9% | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $87.5M | $75.5M | $65.1M | $45.2M | $31.6M | $21.8M | $15.3M | $53.0M |
| Liabilities | $20.9M | $16.4M | $13.5M | $16.4M | $16.3M | $8.6M | $9.9M | $10.5M |
| Equity | $66.6M | $59.2M | $51.6M | $28.8M | $15.3M | $13.2M | $5.4M | $42.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-15.0M | $-11.1M | $-9.2M | $-20.7M | $-12.7M | $-8.8M | $-5.3M | $-6.5M |